Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
HCA Healthcare operates 186 hospitals and approximately 2,400 ambulatory sites across 20 U.S. states and the U.K., making it America's largest for-profit hospital operator. The company dominates key metropolitan markets including Nashville, Denver, Las Vegas, and Florida's Gulf Coast, generating revenue through patient admissions, outpatient procedures, and emergency room visits reimbursed by commercial insurers (45-50%), Medicare/Medicaid (40-45%), and self-pay patients. Stock performance is driven by same-facility admission growth, commercial payor mix, labor cost management, and capital deployment through aggressive share buybacks enabled by $7.7B annual free cash flow.
HCA generates revenue per admission of approximately $15,000-20,000 for inpatient stays and $1,500-3,000 for ER visits, with profitability heavily dependent on payor mix. Commercial insurance reimbursement rates run 200-300% of Medicare rates, making commercial mix the primary margin driver. The company achieves 41.5% gross margins through scale advantages in supply chain procurement, physician network density creating referral patterns, and market dominance in key geographies allowing pricing power with commercial payors. Operating leverage is moderate-to-high: fixed costs include facility maintenance, administrative overhead, and baseline staffing, while variable costs include nursing labor (largest expense at ~40% of revenue), medical supplies, and physician fees. Same-facility revenue growth of 4-6% annually drops significantly to EBITDA due to operating leverage.
Same-facility admission growth and case mix intensity (surgical vs. medical admissions)
Commercial insurance payor mix percentage - every 100bps shift impacts EBITDA margins by 50-75bps
Nursing labor costs and contract labor utilization rates - contract labor runs 2-3x permanent staff costs
Medicare Advantage penetration growth (currently ~30% of Medicare patients, growing 8-10% annually)
Share repurchase authorization and execution - company typically retires 4-6% of shares outstanding annually
Regulatory developments affecting reimbursement rates (CMS Medicare rate updates, Medicaid expansion)
Medicare reimbursement rate pressure as federal deficit concerns mount - CMS rates growing below medical cost inflation would compress margins on 35-40% of revenue
Shift toward value-based care and bundled payments reducing fee-for-service revenue opportunities
Nursing labor shortage driving structural wage inflation - U.S. projects 275,000 nurse shortage by 2025, forcing reliance on expensive contract labor
Regulatory risk from potential Medicare-for-All or public option legislation eliminating high-margin commercial insurance
Ambulatory surgery center migration pulling profitable outpatient procedures away from hospital campuses - ASCs operate at 40-50% lower cost structure
Payor consolidation (UnitedHealth, Anthem, CVS/Aetna vertical integration) increasing negotiating leverage against hospital systems
Non-profit hospital competitors expanding in HCA markets with tax-exempt financing advantages and mission-driven physician loyalty
High leverage with Debt/Equity of -8.33x and $37B gross debt creates refinancing risk and interest rate sensitivity, though offset by strong $12.6B operating cash flow
Negative tangible equity from aggressive share repurchases limits financial flexibility during severe downturns
Pension and post-retirement benefit obligations, though relatively modest for healthcare sector
Accounts receivable concentration risk - top 5 payors represent 50-55% of revenue, creating collection risk if major payor disputes claims
moderate - Healthcare utilization demonstrates relative recession resilience for emergency and non-deferrable procedures (60-65% of volume), but elective surgeries and outpatient procedures decline 5-10% during recessions as patients delay care due to employment loss, insurance coverage gaps, or higher deductible plans. Commercial insurance enrollment correlates directly with employment levels, and unemployment spikes shift payor mix toward lower-reimbursing Medicaid or uncompensated care. However, counter-cyclically, Medicaid expansion during downturns can partially offset commercial insurance losses.
Rising rates increase HCA's interest expense on $37B debt (mix of fixed and floating), with every 100bps rate increase adding approximately $150-200M annual interest cost on floating-rate exposure. More significantly, higher rates compress valuation multiples for cash flow generative healthcare stocks as investors rotate toward fixed income. Conversely, lower rates reduce financing costs for HCA's aggressive capital deployment strategy (acquisitions, facility expansion, share buybacks) and expand valuation multiples. The company's negative equity position (due to leveraged buybacks) amplifies ROE sensitivity to rate changes.
Moderate exposure through patient credit risk and insurance reimbursement. Self-pay and uninsured patients represent 4-6% of revenue but 15-20% of bad debt expense. Rising unemployment increases uncompensated care and Medicaid mix. Commercial insurance financial health matters - payor bankruptcies or delayed reimbursements impact DSO and working capital. HCA maintains strong investment-grade credit ratings (BBB/Baa2) enabling access to capital markets for refinancing $37B debt stack.
value and capital return - HCA attracts investors seeking cash flow generation, aggressive share buybacks (4-6% annual share count reduction), and defensive healthcare exposure with moderate growth. The 6.4% FCF yield and consistent capital return program appeal to value investors, while 28.5% EPS growth (driven partially by buybacks) attracts GARP investors. Not a dividend story (minimal payout) but rather a buyback-driven value creation model. Recent 67.8% one-year return reflects multiple expansion as investors recognize durable cash generation and operational execution.
moderate - Beta typically 0.9-1.1, lower than broader market due to healthcare defensive characteristics but higher than hospital peers due to for-profit structure and leverage. Earnings volatility driven by quarterly fluctuations in flu season severity, elective procedure volumes, and payor mix shifts. Stock experiences sharp moves on regulatory headlines (Medicare-for-All proposals, surprise billing legislation) and quarterly earnings beats/misses on same-facility metrics.
